According to TipRanks.com, Sykes ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.5% and a 39.4% success rate. Sykes covers the Healthcare sector, focusing on stocks such as Singular Genomics Systems, Nautilus Biotechnolgy, and Mettler-Toledo.
Currently, the analyst consensus on PerkinElmer is a Hold with an average price target of $165.00, a 23.6% upside from current levels. In a report issued on July 5, Evercore ISI also downgraded the stock to Hold with a $150.00 price target.
PerkinElmer’s market cap is currently $17.29B and has a P/E ratio of 22.43.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.
Read More on PKI: